Table S1: Details of the 1st survey

Respondent details

Name of responding doctor	Free text
Date of response	Free text
Hospital / Institution	Free text
Country	Free text
email	Free text

General basic information (overview)

Total number of tests to date at your institution	number					
Age	Drop down	0-1y: number	1-4y: number	4-6y: number	6-12y: number	>12y: number
Sex	Drop down	girls: number	boys: number			
Underlying conditions (diagnoses of the children)	Drop down	asthma: number	cystic fibrosis: number	broncho- pulmonary dysplasia (BPD): number	others: free text	
Admissions (after diagnosis of COVID-19 infection)	Drop down	home: number	ward: number	PICU: number		

<u>Asthma</u>

Total number of Children (<16 yrs) with Asthma and COVID-19	number						
				Upper respiratory			
Presenting diagnosis	drop down	Exacerbation: number	Pneumonia: number	tract infection:	fever only: number	asymptomatic:	other: free text

	1		1	T	1		
Admissions (after diagnosis of COVID-19 infection)	Drop down	home: number	ward: number	PICU: number			
Number of days hospitalized (if several children median and range)	number						
Number of days with symptoms (defined as WHO symptoms, time until free of symptoms for >=24hrs; if several children median and range)	number						
Pre-admission treatment GINA Step	Drop down	Step 1: number	Step 2: number	Step 3: number	Step 4: number	Step 5: number	
Predominant X-ray changes	Drop down	Not done	Ground glass opacity	Local patchy shadowing	Bilateral patchy shadowing	Interstitial abnormalities	
CT changes if applicable	Drop down	Not done	Ground glass opacity	Local patchy shadowing	Bilateral patchy shadowing	Interstitial abnormalities	
Treatment	Drop down	None	Oxygen: number	Hogh-Flow nasal cannula: number	Non-invasive ventilation: : number	Invasive ventilation: number	
			Antibiotics: number	Azitromycine: number	experimental COVID treatment: free text		
Number of deaths	Number						

Cystic fibrosis

Total number of Children (<16 yrs) with CF and COVID-19	number						
Presenting diagnosis	drop down	Exacerbation: number	Pneumonia: number	Upper respiratory tract infection: number	fever only: number	asymptomatic: number	other: free text
Admissions (after diagnosis of COVID-19 infection)	Drop down	home: number	ward: number	PICU: number			

Number of days hospitalized (if several	numb an						
children median and range) Number of days with symptoms (defined as WHO symptoms, time until free of symptoms for >=24hrs; if several children median and range)	number						
If available last FEV1% (or zscores)	Drop down	not done: number	>80% (zscore <1.69): number	40-79%: number	<40%: number		
Predominant X-ray changes	Drop down	Not done	Ground glass opacity	Local patchy shadowing	Bilateral patchy shadowing	Interstitial abnormalities	
CT changes if applicable	Drop down	Not done	Ground glass opacity	Local patchy shadowing	Bilateral patchy shadowing	Interstitial abnormalities	
Treatment	Drop down	None	Oxygen: number	Hogh-Flow nasal cannula: number	Non-invasive ventilation: : number	Invasive ventilation: number	
			Antibiotics: number	Azitromycine: number	experimental COVID treatment: free text		
Number of deaths	Number						

Bronchopulmonary Dysplasia (BPD)

Total number of Children (<16 yrs) with BPD and COVID-19	number						
Severity of BDP	Drop down	mild: number	moderate: number	severe: number			
		Exacerbation:	Pneumonia:	Upper respiratory tract infection:	fever only:	asymptomatic:	
Presenting diagnosis	drop down	number	number	number	number	number	other: free text

Admissions (after diagnosis of COVID-19 infection)	Drop down	home: number	ward: number	PICU: number			
Number of days hospitalized (if several children median and range)	number						
Number of days with symptoms (defined as WHO symptoms, time until free of symptoms for >=24hrs; if several children median and range)	number						
If available last FEV1% (or zscores)	Drop down	not done: number	>80% (zscore <1.69): number	40-79%: number	<40%: number		
Predominant X-ray changes	Drop down	Not done	Ground glass opacity	Local patchy shadowing	Bilateral patchy shadowing	Interstitial abnormalities	
CT changes if applicable	Drop down	Not done	Ground glass opacity	Local patchy shadowing	Bilateral patchy shadowing	Interstitial abnormalities	
Treatment	Drop down	None	Oxygen: number	Hogh-Flow nasal cannula: number	Non-invasive ventilation: : number	Invasive ventilation: number	
			Antibiotics:	Azitromycine:	experimental COVID treatment: free text		
Number of deaths	Number						

Other underlying respiratory conditions

Total number of Children (<16 yrs) with other underlying respiratory conditions and COVID-							
19	number						
Diagnosis (underlying condition)	drop down	free text					

		Exacerbation:	Pneumonia:	Upper respiratory tract infection:	fever only:	asymptomatic:	
Presenting diagnosis	drop down	number	number	number	number	number	other: free text
Admissions (after diagnosis of COVID-19 infection)	Drop down	home: number	ward: number	PICU: number			
Number of days hospitalized (if several children median and range)	number						
Number of days with symptoms (defined as WHO symptoms, time until free of symptoms for >=24hrs; if several children median and range)	number						
If available last FEV1% (or zscores)	Drop down	not done: number	>80% (zscore <1.69): number	40-79%: number	<40%: number		
Predominant X-ray changes	Drop down	Not done	Ground glass opacity	Local patchy shadowing	Bilateral patchy shadowing	Interstitial abnormalities	
CT changes if applicable	Drop down	Not done	Ground glass opacity	Local patchy shadowing	Bilateral patchy shadowing	Interstitial abnormalities	
Treatment	Drop down	None	Oxygen: number	Hogh-Flow nasal cannula: number	Non-invasive ventilation: : number	Invasive ventilation: number	
			Antibiotics: number	Azitromycine: number	experimental COVID treatment: free text		